Emerging Generics and Manufacturers of the Pharmaceutical Industry in Bangladesh

Abstract

Because of the large population and industrialization, the pharmaceutical industry in Bangladesh is growing fast. Which generics are leading the pharma industry? This study is designed to depict the overall pharma industry value and growth rate along with the emerging generics and manufacturers of the industry. The required data for this study have been collected from IQVIA. The pharmaceutical market of Bangladesh was TK 212.26 billion along with 1,183 generics and 230 manufacturers in MAT 4Q, 2018. After 5 years, in MAT 4Q, 2022, the industry returned to TK 294.59 billion along with 1,246 generics and 178 manufacturers. The industry is expanding gradually, but the small firms are either losing market share or leaving the industry meaning that the industry is converging toward the large firms. The top 20 manufacturers are controlling 91.5% of the industry. The ESOMEPRAZOLE is taking the market share from the OMEPRAZOLE, RABEPRAZOLE. The PREGABALIN showed the highest growth rate among the top 20 generics in MAT 4Q, 2022. The top 20 generics are controlling 37.2% of the industry. The generics-wise and manufacturers-wise market share in this study is the static picture of MAT 4Q, 2022. Industry practitioners, researchers, and other stakeholders might be used this study to understand the pharma industry of Bangladesh for their future business or research.